Our Breast Cancer patients and their families strongly disagree that the use of Leronlimab was useless.
I expect CYDY management to invest the profits from Brazil , once Approved, into Cancer Trials.
The patients that have observed the tumors reduction to close to zero and their Doctors will have a large influence on new patients joining our future FDA Approved Cancer Trials.
Once Brazil Approves the Wonder Drug we will have decent revenues is just the first step. Spending our shareholder funds savinf the many ladies lives is such a worthy objective.
Not exactly. I asked the FDA about that non-trial patient data and this data will not be considered on its own but in conjunction with trial data, yes. The problem I see is that the number of trial patients being used (10) is too small and gives the FDA cover to say “get 50 patients” and come back. NP is spin this as a positive of course. NP is incompetence personified.
Market Data 
Markets 
AI
